| Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis (NCT01955733) | Boehringer Ingelheim | 2013-05-31 |
| Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets (NCT01845077) | Boehringer Ingelheim | 2013-05-01 |
| Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients (NCT01858961) | Boehringer Ingelheim | 2013-05-01 |
| Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers (NCT01841112) | Boehringer Ingelheim | 2013-04-22 |
| Anticoagulant Utilization Pattern (NCT01847560) | Boehringer Ingelheim | 2013-04-17 |
| Safety of Single Rising Doses and Relative Bioavailability of BI 691751 (NCT01843972) | Boehringer Ingelheim | 2013-04-01 |
| BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 (NCT01830127) | Boehringer Ingelheim | 2013-04-01 |
| ADAM-Afatinib Diarrhea Assessment and Management (NCT01814553) | Boehringer Ingelheim | 2013-04-01 |
| Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution (NCT01835899) | Boehringer Ingelheim | 2013-04-01 |
| Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets (NCT01844531) | Boehringer Ingelheim | 2013-04-01 |
| Comparative Effectiveness of Oral Anticoagulants (NCT01847547) | Boehringer Ingelheim | 2013-04-01 |
| Preference Tiotropium Respimat Study in COPD (NCT01810692) | Boehringer Ingelheim | 2013-03-01 |
| Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together (NCT01811953) | Boehringer Ingelheim | 2013-03-01 |
| Pharmacokinetics of Faldaprevir of Soft Capsule (NCT01821937) | Boehringer Ingelheim | 2013-03-01 |
| Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes (NCT01734785) | Boehringer Ingelheim | 2013-02-08 |
| Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours (NCT01772563) | Boehringer Ingelheim | 2013-02-04 |
| Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir (NCT01785160) | Boehringer Ingelheim | 2013-02-01 |
| Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin (NCT01795937) | Boehringer Ingelheim | 2013-02-01 |
| MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin (NCT01792518) | Boehringer Ingelheim | 2013-02-01 |
| Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) (NCT01721876) | Boehringer Ingelheim | 2013-01-29 |
| SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea (NCT01774370) | Boehringer Ingelheim | 2013-01-14 |
| To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706 (NCT01763333) | Boehringer Ingelheim | 2013-01-08 |
| Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes (NCT01778049) | Boehringer Ingelheim | 2013-01-01 |
| Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin (NCT01770392) | Boehringer Ingelheim | 2013-01-01 |
| Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age (NCT01773174) | Boehringer Ingelheim | 2013-01-01 |
| Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects (NCT01787032) | Boehringer Ingelheim | 2013-01-01 |
| Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions (NCT01764945) | Boehringer Ingelheim | 2013-01-01 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (NCT01751776) | Boehringer Ingelheim | 2012-12-18 |
| IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 (NCT01732796) | Boehringer Ingelheim | 2012-12-01 |
| A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus (NCT01707147) | Boehringer Ingelheim | 2012-11-16 |
| An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms (NCT01726270) | Boehringer Ingelheim | 2012-11-01 |
| Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor (NCT01734772) | Boehringer Ingelheim | 2012-11-01 |
| Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 (NCT01728324) | Boehringer Ingelheim | 2012-11-01 |
| Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers (NCT01734902) | Boehringer Ingelheim | 2012-11-01 |
| Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects (NCT01737996) | Boehringer Ingelheim | 2012-11-01 |
| Nonivamide/Nicoboxil Ointment in Acute Low Back Pain (NCT01708915) | Boehringer Ingelheim | 2012-10-01 |
| Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease. (NCT01711853) | Boehringer Ingelheim | 2012-10-01 |
| Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes (NCT01719003) | Boehringer Ingelheim | 2012-10-01 |
| Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation) (NCT01703286) | Boehringer Ingelheim | 2012-10-01 |
| Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients (NCT01708902) | Boehringer Ingelheim | 2012-10-01 |
| Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment (NCT01721837) | Boehringer Ingelheim | 2012-10-01 |
| A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy (NCT01649297) | Boehringer Ingelheim | 2012-10-01 |
| Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers (NCT01707940) | Boehringer Ingelheim | 2012-10-01 |
| A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD. (NCT01703845) | Boehringer Ingelheim | 2012-10-01 |
| Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules (NCT01704846) | Boehringer Ingelheim | 2012-10-01 |
| BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse (NCT01690624) | Boehringer Ingelheim | 2012-09-13 |
| Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis (NCT01682512) | Boehringer Ingelheim | 2012-09-05 |
| Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® (NCT01696058) | Boehringer Ingelheim | 2012-09-01 |
| A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection (NCT01608737) | Boehringer Ingelheim | 2012-09-01 |
| Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers (NCT01679613) | Boehringer Ingelheim | 2012-09-01 |
| Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers (NCT01681277) | Boehringer Ingelheim | 2012-09-01 |
| Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608 (NCT01703858) | Boehringer Ingelheim | 2012-09-01 |
| Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate (NCT01688830) | Boehringer Ingelheim | 2012-09-01 |
| Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® (NCT01694771) | Boehringer Ingelheim | 2012-09-01 |
| Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication (NCT01696071) | Boehringer Ingelheim | 2012-09-01 |
| Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir (NCT01694706) | Boehringer Ingelheim | 2012-09-01 |
| GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States) (NCT01671007) | Boehringer Ingelheim | 2012-08-22 |
| Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2 (NCT01662986) | Boehringer Ingelheim | 2012-08-01 |
| Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1 (NCT01663987) | Boehringer Ingelheim | 2012-08-01 |
| Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone (NCT01637922) | Boehringer Ingelheim | 2012-08-01 |
| Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) (NCT01662505) | Boehringer Ingelheim | 2012-08-01 |
| Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets (NCT01672788) | Boehringer Ingelheim | 2012-08-01 |
| Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus (NCT01650259) | Boehringer Ingelheim | 2012-07-23 |
| Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. (NCT01649271) | Boehringer Ingelheim | 2012-07-23 |
| Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers (NCT01638598) | Boehringer Ingelheim | 2012-07-01 |
| Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma (NCT01634139) | Boehringer Ingelheim | 2012-07-01 |
| Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX (NCT01652742) | Boehringer Ingelheim | 2012-07-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects (NCT01629849) | Boehringer Ingelheim | 2012-07-01 |
| Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma (NCT01634113) | Boehringer Ingelheim | 2012-07-01 |
| Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers. (NCT01650155) | Boehringer Ingelheim | 2012-07-01 |
| A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations (NCT01647711) | Boehringer Ingelheim | 2012-07-01 |
| Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma (NCT01634152) | Boehringer Ingelheim | 2012-07-01 |
| Afatinib Expanded Access Program (NCT01649284) | Boehringer Ingelheim | 2012-07-01 |
| Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients (NCT01651598) | Boehringer Ingelheim | 2012-07-01 |
| Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (NCT01619085) | Boehringer Ingelheim | 2012-06-06 |
| Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid (NCT01634100) | Boehringer Ingelheim | 2012-06-01 |
| Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus (NCT01826370) | Boehringer Ingelheim | 2012-05-01 |
| Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (NCT01594125) | Boehringer Ingelheim | 2012-05-01 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306 (NCT01611311) | Boehringer Ingelheim | 2012-05-01 |
| Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects (NCT01608087) | Boehringer Ingelheim | 2012-05-01 |
| Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran (NCT01595854) | Boehringer Ingelheim | 2012-05-01 |
| Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers (NCT01605461) | Boehringer Ingelheim | 2012-05-01 |
| Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers (NCT01594515) | Boehringer Ingelheim | 2012-05-01 |
| Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes (NCT01581658) | Boehringer Ingelheim | 2012-04-01 |
| Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets (NCT01581931) | Boehringer Ingelheim | 2012-04-01 |
| Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX (NCT01587391) | Boehringer Ingelheim | 2012-04-01 |
| Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL (NCT01587417) | Boehringer Ingelheim | 2012-04-01 |
| Drug-drug Interaction of BI 201335 and Microgynon (NCT01570244) | Boehringer Ingelheim | 2012-04-01 |
| Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients (NCT01525628) | Boehringer Ingelheim | 2012-04-01 |
| Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial (NCT01579474) | Boehringer Ingelheim | 2012-04-01 |
| Safety Tolerability and Pharmacokinetic of BI 411034 (NCT01581684) | Boehringer Ingelheim | 2012-04-01 |
| Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment (NCT01580306) | Boehringer Ingelheim | 2012-04-01 |
| LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy (NCT01523587) | Boehringer Ingelheim | 2012-03-05 |
| Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients (NCT01533922) | Boehringer Ingelheim | 2012-03-01 |
| Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease (NCT01559116) | Boehringer Ingelheim | 2012-03-01 |
| Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice (NCT01524900) | Boehringer Ingelheim | 2012-03-01 |
| Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease (NCT01525641) | Boehringer Ingelheim | 2012-02-01 |
| Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. (NCT01533935) | Boehringer Ingelheim | 2012-02-01 |
| Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers (NCT01535638) | Boehringer Ingelheim | 2012-02-01 |
| Japan Long-term Safety for Tiotropium Plus Olodaterol (NCT01536262) | Boehringer Ingelheim | 2012-02-01 |